Access Accelerated

What Access Accelerated does

Access Accelerated is a Geneva-headquartered multi-stakeholder collective initiative founded in January 2017 at the World Economic Forum in Davos by 22 biopharmaceutical companies. It operates under the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), which serves as the Secretariat, and currently unites more than 20 life sciences companies including Pfizer, Novartis, Roche, Johnson & Johnson, Merck, Bristol Myers Squibb, Sanofi, Takeda, Eli Lilly, GSK, Bayer, MSD, Astellas, Eisai, Novo Nordisk, Daiichi Sankyo, Chugai, Menarini, Ono Pharmaceutical, UCB, and Sumitomo Pharma. The initiative's purpose is to improve prevention and treatment of non-communicable diseases (NCDs)—which cause more than 41 million deaths annually and 77% of those deaths in low- and middle-income countries (LMICs)—through catalytic financing, health systems strengthening, advocacy, and knowledge sharing.

Its core programmatic offerings include the Access Accelerated Open Platform (a centralized knowledge repository and dashboard), the NCD Navigator (a digital information system piloted in Ghana), and the Financing Accelerator Network for NCDs (FAN, launched in 2024). The initiative channels funding through a World Bank Trust Fund—over $25 million contributed between 2017–2023 supporting 44 activities across several dozen LMICs—and partners with the World Bank Group, UICC, PATH, NCD Alliance, Boston University's Access Observatory, Chatham House, and Results for Development. Programs span health financing, universal health coverage, primary care strengthening, and policy advisory across countries including Bangladesh, Republic of Congo, Serbia, Ghana, Kenya, Vietnam, Chile, Colombia, El Salvador, Paraguay, Peru, and Kosovo.

The business model is not commercial. Access Accelerated is funded exclusively by membership contributions from participating biopharmaceutical companies rather than fees for products or services. With 1–10 employees, a thin cost base, and programmatic rather than product-based delivery, it functions as a coordination and advocacy platform rather than a revenue-generating enterprise. The initiative is led by Executive Director Herb Riband (in role since June 2023) and is currently executing Phase 3 (2024–2026), following Phase 1 (2017–2019) and Phase 2 (2020–2023).

Name

Access Accelerated

Legal name

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Website

https://accessaccelerated.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Access Accelerated is a Geneva-based collective of 20+ biopharmaceutical companies, operating under IFPMA, that partners with the World Bank and global health NGOs to address non-communicable diseases in low- and middle-income countries through catalytic financing, health systems strengthening, and knowledge sharing programs.

Ownership category

akta.pro rank

Product category

Global Health Partnership and NCD Programs

NAICS

Social Advocacy Organizations (8133), Human Rights Organizations (813311)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Non-Communicable Disease Prevention & Chronic Disease Programs (BPAIAJAI)

akta.pro secondary industries

Public Health Financing, Budgeting & Grants Management (HLAJAMAC), Public Health Governance, Interagency Coordination & Partnerships (HLAJAMAD)

Keywords

• Global health partnership
• Noncommunicable disease programs
• Health financing initiatives
• Pharmaceutical collective
• Low-middle income countries

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Membership contributions: Access Accelerated is funded by contributions from its member biopharmaceutical and life science companies. As a collective initiative focused on improving NCD care in LMICs rather than generating commercial revenue, the organization operates as a multi-stakeholder partnership without traditional revenue streams.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Access Accelerated is a multi-stakeholder collective of more than 20 leading biopharmaceutical and life science companies that coordinates programs, funding, and partnerships to improve prevention, treatment, and financing of noncommunicable diseases (NCDs) in low- and middle-income countries. The initiative operates through the World Bank Trust Fund, knowledge-sharing platforms, and country-level partnerships with governments and NGOs to advance sustainable NCD responses.

Product overview

Access Accelerated is a global coalition of biopharmaceutical and life science companies united to address noncommunicable diseases (NCDs) in low- and middle-income countries. The organization operates several interconnected programs: the Access Accelerated Open Platform serves as a knowledge repository and dashboard for tracking NCD initiatives; the Financing Accelerator Network for NCDs (FAN) focuses on catalyzing sustainable financing for NCD care; and the NCD Navigator provides digital information systems for country-level NCD program management. These programs work in concert with World Bank partnerships to improve health financing, advance universal health coverage, strengthen health systems and primary care, and facilitate knowledge sharing across the global NCD response network.

Differentiator

Problem solved

Functional benefit

Brands

• Financing Accelerator Network for NCDs (FAN): An initiative of Access Accelerated launched in 2024 to advance sustainable financing for noncommunicable diseases in low- and middle-income countries. FAN published its first annual report marking the first full year of implementation.

Products and services

• Access Accelerated Open Platform A digital knowledge resource and dashboard that provides a centralized information repository and data visualization for NCD programs, research efforts, partnerships, and advocacy materials. Used by global health stakeholders, researchers, and policymakers.
• NCD Navigator A digital information system for tracking and managing NCD-related data at country level. Stewardship was transferred to Ghana Health Service's NCD Control Programme, demonstrating sustainability and country ownership of NCD program data management.
• Financing Accelerator Network for NCDs (FAN) An initiative focused on accelerating sustainable financing for NCDs in low- and middle-income countries, working with country-level stakeholders to catalyze investment, unlock innovative funding avenues, and advance health financing solutions for NCD care.

Quantifiable outcome

• 44 World Bank activities supported at global, regional, and national levels across several dozen LMICs (2017-2023)
• +1 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

33 partnerships are on record, tiered flagship, core and secondary.

• World Bank GroupflagshipStrategic or Co-development Partner · 18 January 2017Access Accelerated partners with the World Bank to identify solutions addressing financing, regulatory, and service delivery barriers at country level. The World Bank conducts pilots in primary care to improve NCD outcomes. Between 2017-2023, Access Accelerated contributed over $25 million to a World Bank Trust Fund supporting 44 activities across multiple LMICs.
• Union for International Cancer Control (UICC)coreStrategic or Co-development Partner · 18 January 2017Access Accelerated serves as a foundational partner of UICC's C/Can 2025: City Cancer Challenge, working to improve cancer treatment and care in cities worldwide, with initial learning cities including Cali (Colombia), Asuncion (Paraguay), and Yangon (Myanmar).
• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations)flagshipStrategic or Co-development Partner · 18 January 2017IFPMA acts as the Secretariat for Access Accelerated and hosts the initiative's headquarters in Geneva, Switzerland. IFPMA provides administrative and operational support for the collective.
• PATHcoreStrategic or Co-development PartnerPATH works to improve access to person-centered primary healthcare and has collaborated on NCD programs including the NCD Navigator initiative in Ghana and hypertension management programs in Vietnam.
• NCD AlliancecoreStrategic or Co-development PartnerAccess Accelerated supports the NCD Alliance to elevate voices of people living with NCDs, build advocacy capacity, and advance people-centered approaches to NCD policy and care.
• Boston University Access ObservatorycoreStrategic or Co-development PartnerBoston University designed and manages the Access Observatory, an independent measurement framework to establish a foundation for shared learning and measure the effectiveness of Access Accelerated programs.
• Chatham HousesecondaryStrategic or Co-development PartnerCollaborative partner for expert dialogues on improving access to healthcare, including measurement and reporting to support global partnerships.
• Results for DevelopmentsecondaryStrategic or Co-development PartnerTechnical partner working with Access Accelerated and World Bank to build coalitions aimed at closing the health financing gap for NCDs.
• Resolve Global HealthsecondaryStrategic or Co-development PartnerCollaborative partner contributing to reports and discussions on health financing and market-shaping approaches for NCD care access in LMICs.
• Bristol Myers SquibbcoreOthersMember company of Access Accelerated since 2017, contributing expertise, innovation, and resources to collective NCD programs.
• Novo NordiskcoreOthersMember company contributing to Access Accelerated's mission, including participation through Health Equity Lead Carissa Vados and Vice Chair representation.
• SanoficoreOthersSanofi's Global Health Unit joined Access Accelerated in 2025 as the newest member company, with shared commitment to advancing impact for NCD financing in LMICs.
• TakedacoreOthersMember company, with Takanori Sato serving as Co-chair of the Access Accelerated Steering Committee.
• Eli Lilly and CompanycoreOthersMember company contributing to the collective effort to address NCDs in LMICs.
• RochecoreOthersMember company involved in Access Accelerated since its founding, contributing to cancer care and NCD programs.
• NovartiscoreOthersMember company contributing to Access Accelerated's NCD programs and initiatives.
• PfizercoreOthersMember company; Ian Read, then CEO of Pfizer and President of IFPMA, announced Access Accelerated's launch at the World Economic Forum in 2017.
• Johnson & JohnsoncoreOthersMember company contributing to the collective NCD access programs.
• MSDcoreOthersMember company participating in Access Accelerated's collaborative approach to NCDs.
• MerckcoreOthersMember company contributing to Access Accelerated's mission.
• BayercoreOthersMember company participating in collective NCD programs.
• Astellas PharmacoreOthersMember company of Access Accelerated.
• EisaicoreOthersMember company contributing to Access Accelerated.
• Chugai PharmaceuticalcoreOthersMember company of Access Accelerated.
• Daiichi SankyocoreOthersMember company participating in Access Accelerated.
• MenarinicoreOthersMember company of Access Accelerated.
• UCBcoreOthersMember company contributing to Access Accelerated's NCD initiatives.
• Ono PharmaceuticalcoreOthersMember company of Access Accelerated.
• GlaxoSmithKlinecoreOthersMember company participating in Access Accelerated.
• Sumitomo PharmacoreOthersMember company of Access Accelerated.
• ServiersecondaryOthersGlobal biopharmaceutical company that joined Access Accelerated in April 2019 to address the growing NCD burden.
• IpsensecondaryOthersGlobal biopharmaceutical company that joined Access Accelerated in April 2019.
• MedAccesssecondaryStrategic or Co-development PartnerPartner featured in event reports presenting financing models aimed at expanding access to NCD care.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Gavi, the Vaccine Alliance: Public-private partnership pooling resources from governments, pharma, and foundations to scale health interventions in LMICs. Most structurally analogous peer to Access Accelerated — multi-stakeholder collective model, IFPMA-member pharma participation, and focus on access to health products in low-income countries.
• PATH: Global nonprofit that designs and implements health solutions in LMICs, partnering with governments, donors, and private sector. Direct peer and partner of Access Accelerated; similar operating model in country-level NCD and primary care strengthening.
• UNITAID: Global health partnership hosted by WHO that identifies and scales innovations to address HIV, TB, malaria, and increasingly NCDs in LMICs. Comparable pooled-financing model targeting global health product access with strong institutional partnerships.
• NCD Alliance: Global network of civil society organizations and dedicated NCD advocacy platform. Direct peer in NCD-focused mission; Access Accelerated is both partner and adjacent — NCD Alliance leads advocacy while Access Accelerated leads financing/programmatic work.
• Global Financing Facility for Women, Children and Adolescents (GFF): World Bank-hosted multi-stakeholder financing partnership catalyzing country-led investments in health. Highly comparable mechanism to Access Accelerated's Trust Fund arrangement with the World Bank, focused on sustainable health financing in LMICs.
• Medicines Patent Pool: UN-backed public health organization funded by governments and foundations that works with pharma holders to license essential medicines for LMIC production. Highly comparable as a biopharma-engaged access-to-medicines collective operating through international institutional partnerships.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria: Multilateral financing partnership that mobilizes and channels large-scale resources from public and private donors to country-led health programs. Closely comparable financing-collective model with explicit focus on LMIC disease burden — the template Access Accelerated effectively adapted for NCDs.
• Coalition for Epidemic Preparedness Innovations (CEPI): Coalition of public, private, philanthropic, and civil society organizations funding vaccine development against epidemic threats. Comparable multi-stakeholder coalition governance model with pharma members, focused on global health preparedness.

Broad incumbents

• Wellcome Trust: Major global charitable foundation funding health research and access initiatives, including substantial NCD-related work. Comparable as a large, well-resourced global health funder whose priorities shape the same LMIC-access space as Access Accelerated.
• World Health Organization (WHO) NCD Department: UN specialized agency with global mandate on NCD prevention and control, including policy guidance and country-level support. Functions as the broader public-sector incumbent shaping the global NCD agenda in which Access Accelerated operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ncdaccess
• LinkedInlinkedin.com/company/access-accelerated

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Access Accelerated